<DOC>
	<DOCNO>NCT00000802</DOCNO>
	<brief_summary>To compare efficacy safety dapsone versus atovaquone prevent delay onset histologically proven probable Pneumocystis carinii pneumonia HIV-infected patient CD4 count &lt; = 200 cells/mm3 &lt; = 15 percent total lymphocyte count intolerant trimethoprim and/or sulfonamide . Trimethoprim/sulfamethoxazole ( TMP/SMX ) , effective secondary PCP prophylaxis , associate allergic manifestation side effect limit use . Patients intolerant TMP/SMX require effective alternative . Dapsone atovaquone show promise PCP prophylactic agent .</brief_summary>
	<brief_title>A Randomized , Comparative Study Daily Dapsone Daily Atovaquone Prophylaxis Against PCP HIV-Infected Patients Who Are Intolerant Trimethoprim and/or Sulfonamides</brief_title>
	<detailed_description>Trimethoprim/sulfamethoxazole ( TMP/SMX ) , effective secondary PCP prophylaxis , associate allergic manifestation side effect limit use . Patients intolerant TMP/SMX require effective alternative . Dapsone atovaquone show promise PCP prophylactic agent . Patients randomize receive either dapsone atovaquone daily , follow-up clinic every 4 month .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Strongly recommend : Pyrimethamine ( 50 mg ) folinic acid ( 15 mg ) weekly patient receive dapsone CD4 count &lt; 100 cells/mm3 toxoplasmosis seropositive . Patients must : Working diagnosis HIV infection . CD4 count &lt; = 200 cells/mm3 &lt; = 15 percent total lymphocyte count time past OR history PCP . History intolerance trimethoprim and/or sulfonamide require permanent discontinuation . NOTE : Pregnant patient eligible clinician 's discretion . Prior Medication : Allowed : Prior PCP prophylaxis . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active pneumocystosis . Concurrent Medication : Excluded : PCP prophylaxis ( study drug ) medication potential antiPCP activity . Patients follow prior condition exclude : Known treatmentlimiting reaction dapsone atovaquone .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Dapsone</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>atovaquone</keyword>
</DOC>